Logo image of AXDX

ACCELERATE DIAGNOSTICS INC (AXDX) Stock Fundamental Analysis

NASDAQ:AXDX - Nasdaq - US00430H2013 - Common Stock - Currency: USD

0.034  -0.05 (-61.36%)

After market: 0.052 +0.02 (+52.94%)

Fundamental Rating

0

AXDX gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of AXDX have multiple concerns. AXDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AXDX had negative earnings in the past year.
AXDX had a negative operating cash flow in the past year.
In the past 5 years AXDX always reported negative net income.
In the past 5 years AXDX always reported negative operating cash flow.
AXDX Yearly Net Income VS EBIT VS OCF VS FCFAXDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

AXDX has a Return On Assets of -175.26%. This is amonst the worse of the industry: AXDX underperforms 92.06% of its industry peers.
Industry RankSector Rank
ROA -175.26%
ROE N/A
ROIC N/A
ROA(3y)-155.95%
ROA(5y)-129.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AXDX Yearly ROA, ROE, ROICAXDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

With a Gross Margin value of 23.12%, AXDX is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
AXDX's Gross Margin has declined in the last couple of years.
AXDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.89%
GM growth 5Y-13.35%
AXDX Yearly Profit, Operating, Gross MarginsAXDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

AXDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AXDX has more shares outstanding
Compared to 5 years ago, AXDX has more shares outstanding
The debt/assets ratio for AXDX is higher compared to a year ago.
AXDX Yearly Shares OutstandingAXDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
AXDX Yearly Total Debt VS Total AssetsAXDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -39.29, we must say that AXDX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -39.29, AXDX is doing worse than 93.12% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -39.29
ROIC/WACCN/A
WACC0.32%
AXDX Yearly LT Debt VS Equity VS FCFAXDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.71 indicates that AXDX may have some problems paying its short term obligations.
AXDX has a Current ratio of 0.71. This is amonst the worse of the industry: AXDX underperforms 92.59% of its industry peers.
A Quick Ratio of 0.62 indicates that AXDX may have some problems paying its short term obligations.
AXDX has a worse Quick ratio (0.62) than 91.01% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.62
AXDX Yearly Current Assets VS Current LiabilitesAXDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

AXDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.33%, which is quite impressive.
Looking at the last year, AXDX shows a decrease in Revenue. The Revenue has decreased by -2.97% in the last year.
The Revenue has been growing slightly by 4.69% on average over the past years.
EPS 1Y (TTM)35.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.09%
Revenue 1Y (TTM)-2.97%
Revenue growth 3Y-0.23%
Revenue growth 5Y4.69%
Sales Q2Q%-6.97%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.29%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.44%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AXDX Yearly Revenue VS EstimatesAXDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
AXDX Yearly EPS VS EstimatesAXDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AXDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AXDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AXDX Price Earnings VS Forward Price EarningsAXDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXDX Per share dataAXDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AXDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACCELERATE DIAGNOSTICS INC

NASDAQ:AXDX (5/14/2025, 8:20:36 PM)

After market: 0.052 +0.02 (+52.94%)

0.034

-0.05 (-61.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-22 2025-05-22/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners18.91%
Inst Owner Change-6.06%
Ins Owners4.32%
Ins Owner Change2.25%
Market Cap857.14K
Analysts85.71
Price TargetN/A
Short Float %1.89%
Short Ratio0.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.21%
Min EPS beat(2)-23.07%
Max EPS beat(2)25.49%
EPS beat(4)2
Avg EPS beat(4)-2.97%
Min EPS beat(4)-23.07%
Max EPS beat(4)25.49%
EPS beat(8)4
Avg EPS beat(8)8.27%
EPS beat(12)8
Avg EPS beat(12)11.25%
EPS beat(16)9
Avg EPS beat(16)7.76%
Revenue beat(2)0
Avg Revenue beat(2)-5.99%
Min Revenue beat(2)-8.57%
Max Revenue beat(2)-3.41%
Revenue beat(4)0
Avg Revenue beat(4)-4.41%
Min Revenue beat(4)-8.57%
Max Revenue beat(4)-2.74%
Revenue beat(8)0
Avg Revenue beat(8)-9.77%
Revenue beat(12)2
Avg Revenue beat(12)-6.25%
Revenue beat(16)2
Avg Revenue beat(16)-9.26%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)1.67%
Revenue NQ rev (3m)1.67%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.07
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.38
EYN/A
EPS(NY)-2.04
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0.46
BVpS-2.22
TBVpS-2.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -175.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.12%
FCFM N/A
ROA(3y)-155.95%
ROA(5y)-129.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.89%
GM growth 5Y-13.35%
F-Score3
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.88%
Cap/Sales 4.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.62
Altman-Z -39.29
F-Score3
WACC0.32%
ROIC/WACCN/A
Cap/Depr(3y)21.67%
Cap/Depr(5y)26.83%
Cap/Sales(3y)5.75%
Cap/Sales(5y)6.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.09%
EPS Next Y14.29%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.97%
Revenue growth 3Y-0.23%
Revenue growth 5Y4.69%
Sales Q2Q%-6.97%
Revenue Next Year3.44%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.53%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.81%
OCF growth 3YN/A
OCF growth 5YN/A